1. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. DOI:10.1161/CIR.0000000000000659.
2. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119(10):1363-9. DOI:10.1161/CIRCULATIONAHA.108.816082.
3. Bansal N, Zelnick LR, Alonso A, et al. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol CJASN. 2017;12(9):1386-98. DOI:10.2215/CJN.01860217.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. DOI:10.1016/j.kint.2020.06.019.
5. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol JASN. 2009;20(4):705-11. DOI:10.1681/ASN.2007111207.
6. Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: Prevention and management. J Res Med Sci Off J Isfahan Univ Med Sci. 2015;20(11):1112-20. DOI:10.4103/1735-1995.172845.
7. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157(5):805-10. DOI:10.1016/j.ahj.2009.02.005.
8. Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015;65(23):2481-93. DOI:10.1016/j.jacc.2015.03.577.
9. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet Lond Engl. 2010;375(9731):2073-81. DOI:10.1016/S0140-6736(10)60674-5.
10. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331-40. DOI:10.1038/ki.2010.550.
11. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341-52. DOI:10.1038/ki.2010.536.
12. Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem. 2009;46(Pt 3):205-17. DOI:10.1258/acb.2009.009007.
13. Koopman MG, Krediet RT, Koomen GC, et al. Circadian rhythm of proteinuria: consequences of the use of urinary protein:creatinine ratios. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc. 1989;4(1):9-14.
14. Huan L, Yuezhong L, Chao W, HaiTao T. The urine albumin-to-creatinine ratio is a reliable indicator for evaluating complications of chronic kidney disease and progression in IgA nephropathy in China. Clin Sao Paulo Braz. 2016;71(5):243-250. DOI:10.6061/clinics/2016(05)01
15. Vart P, Scheven L, Lambers Heerspink HJ, et al. Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study. Am J Kidney Dis Off J Natl Kidney Found. 2016;67(1):70-8. DOI:10.1053/j.ajkd.2015.05.025.
16. Medcalf EA, Newman DJ, Gorman EG, Price CP. Rapid, robust method for measuring low concentrations of albumin in urine. Clin Chem. 1990;36(3):446-9.
17. Sparkenbaugh EM, Chantrathammachart P, Mickelson J, et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood. 2014;123(11):1747-56. DOI:10.1182/blood-2013-08-523936.
18. Lee I-O, Kratz MT, Schirmer SH, Baumhäkel M, Böhm M. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther. 2012;343(2):253-7. DOI:10.1124/jpet.112.194837.
19. Bea F, Kreuzer J, Preusch M, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26(12):2787-92. DOI:10.1161/01.ATV.0000246797.05781.ad.